Skip to main content
Premium Trial:

Request an Annual Quote

Genome Diagnostics Makes €1M Investment in CRISPR Diagnostics Startup Scope Biosciences

NEW YORK — Transplant diagnostics developer Genome Diagnostics (GenDx) has made a €1 million ($1.2 million) investment in startup Scope Biosciences, the Dutch companies said on Friday.

Scope Biosciences, a spinout of Wageningen University & Research founded in 2020, is developing a CRISPR-based diagnostic technology called ScopeDx that is aimed at infectious diseases including SARS-CoV-2. In August, the company's cofounders published details of the technology with academic collaborators in Nature Communications.

With the funding from GenDx, Scope said it will expand its R&D team and advance its ongoing partnerships. The companies also aim to explore the use of Scope's technology for transplant diagnostics.

"The proprietary ScopeDx CRISPR-diagnostic platform has shown its incredible potential in various applications in the last three years of its development, and with this investment we can bring the first ScopeDx products to the market," Scope CEO Niek Savelkoul said in a statement.

Earlier this year, GenDx received CE-IVD marking for its NGSgo-MX11-3 human leukocyte antigen typing product for organ and stem cell transplantation testing.